Jun 10, 2024 | Affordable Care Act, Caroline Fraker, MedBen Rx, Obesity, Wegovy, Weight loss, Weight loss drugs, Zepbound
While most health plans do not currently cover obesity medications like Wegovy and Zepbound – and MedBen Rx recommends clients continue not to do so – constant media coverage means the calls to do so will only grow. Therefore, employers are increasingly considering...
May 13, 2024 | Diabetes, Kurt Harden, MedBen Rx, MedBen University, Mounjaro, Ozempic, Wegovy, Weight loss, Zepbound
At recent MedBen University roundtables, MedBen President & CEO Kurt Harden examined how the growing public awareness of two diabetes drugs with a desirable side effect – significant weight loss – means that these $1,000-per-month medications are not always being...
Feb 5, 2024 | MedBen News, Online Services, Prescription, Telehealth, Weight loss, Zepbound
A major drug manufacturer is stepping up efforts to make its new weight-loss drug more accessible to potential users. Eli Lilly recently launched LillyDirect, a direct-to-consumer platform that connects obese patients to telehealth doctors who can prescribe the GLP-1...
Nov 14, 2023 | Drug costs, Obesity, Pharmacy, Prescription, Wegovy, Weight loss, Zepbound
In light of all the attention that weight loss drugs have received lately – as well as the pricing havoc these drugs have been causing in some pharmacy plans – the following news items have caught our attention: North Carolina says its health plan will...
Jul 21, 2023 | Diabetes, Medicare, Ozempic, Pharmacy, Prescription, Research, Trulicity, Weight loss
A Kaiser Family Foundation (KFF) analysis of the 10 top-selling prescription drugs under Medicare Part D offers an interesting snapshot of pharmacy spend. The drugs in question comprised less than 1% of all covered drugs in 2021, but made up approximately 22% of total...
Jun 15, 2023 | Obesity, Ozempic, Pharmacy, Prescription, Rx Costs, Semaglutide, Wegovy, Weight loss
Obesity drugs are becoming big business, with a correspondingly big price tag. And with these drugs regularly making headlines, questions about whether or not health plans should cover them grow louder. The highest-profile obesity drug is semaglutide, sold under the...
